1. LUNG TRANSPLANTATION Overall ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

2. NUMBER OF LUNG TRANSPLANTS REPORTED BY YEAR AND PROCEDURE TYPE 15 48 89 192 415 706 908 1079 1202 1323 1340 1472 1450 1478 1552 1599 1725 1699 ISHLT 2006 NOTE: This figure includes only the lung transplants that are reported to the ISHLT Transplant Registry. As such, this should not be construed as representing changes in the number of lung transplants performed worldwide. 1815 J Heart Lung Transplant 2006;25:880-892

3. AVERAGE CENTER VOLUME Lung Transplants: January 1, 1998 - June 30, 2005 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

4. DISTRIBUTION OF TRANSPLANTS BY CENTER VOLUME Lung Transplants: January 1, 1998 - June 30, 2005 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

5. LUNG TRANSPLANTS: Donor Age by Year of Transplant ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

6. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS (1/1985-6/2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

7. AGE DISTRIBUTION OF LUNG TRANSPLANT RECIPIENTS BY ERA ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

8. LUNG TRANSPLANTATION Adult Recipients ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

9. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS (1/1985-6/2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

10. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS BY ERA ISHLT 2006 Mean age by era 1985-1995 = 44.9 years 1996-6/2005 = 48.3 years J Heart Lung Transplant 2006;25:880-892

11. AGE DISTRIBUTION OF ADULT LUNG TRANSPLANT RECIPIENTS BY ERA ISHLT 2006 Mean age by era 1985-1994 = 44.6 years 1995-1999 = 47.3 years 2000-6/2005 = 48.8 years J Heart Lung Transplant 2006;25:880-892

12. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival (Transplants: January 1994 - June 2004) P < 0.0001 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

13. ADULT LUNG TRANSPLANTATION: Indications (1/1995-6/2005) DIAGNOSISSLT (N = 6,663)BLT (N = 6,789)TOTAL (N = 13,452) COPD/Emphysema3,511 (53%)1,636 (24%)5,147 (38%) Idiopathic Pulmonary Fibrosis1,731 (26%)813 (12.0%)2,544 (19%) Cystic Fibrosis159 (2.4%)2,009 (30%)2,168 (16%) Alpha-1446 (7.0%)597 (8.8%)1,063 (7.9%) Primary Pulmonary Hypertension64 (1.0%)461 (6.8%)525 (3.9%) Sarcoidosis141 (2.1%)195 (2.9%)336 (2.5%) Bronchiectasis25 (0.4%)328 (4.8%)353 (2.6%) LAM54 (0.8%)88 (1.3%)142 (1.1%) Congenital Heart Disease13 (0.2%)115 (1.7%)128 (1.0%) Re-Transplant: Obliterative Bronchiolitis 74 (1.1%)71 (1.0%)145 (1.1%) Obliterative Bronchiolitis (Not Re-Transplant) 44 (0.7%)77 (1.1%)121 (0.9%) Re-Transplant: Not Obliterative Bronchiolitis 65 (1.0%)52 (0.8%)117 (0.9%) Connective Tissue Disease37 (0.6%)45 (0.7%)82 (0.6%) Interstitial Pneumonitis20 (0.3%)10 (0.1%)30 (0.2%) Cancer6 (0.1%)10 (0.1%)16 (0.1%) Other253 (3.8%)282 (4.2%)535 (4.0%) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

14. ADULT LUNG TRANSPLANTATION: Distribution of Procedure Type for Major Indications (1990-2004) ISHLT 2006 Year of TX Alpha-1COPDCystic FibrosisIPFPPH DoubleSingleDoubleSingleDoubleSingleDoubleSingleDoubleSingle 199031.968.123.077.094.75.31.898.215.484.6 199120.979.114.985.195.74.315.184.923.876.2 199227.272.817.282.896.83.29.690.425.774.3 199334.165.915.884.293.86.216.783.351.648.4 199435.264.818.381.783.116.913.686.461.039.0 199548.052.020.279.888.311.726.973.189.610.4 199646.653.426.273.885.015.026.873.281.518.5 199746.753.328.171.992.17.921.978.188.711.3 199850.449.629.470.691.88.219.780.384.815.2 199948.351.727.772.389.110.922.177.983.316.7 200057.942.127.772.394.15.931.268.891.38.7 200159.840.226.873.293.56.526.074.089.410.6 200257.142.938.661.495.64.435.864.286.813.2 200368.131.938.761.395.44.639.160.993.56.5 200475.624.441.558.595.44.643.356.795.24.8 J Heart Lung Transplant 2006;25:880-892

15. ADULT LUNG TRANSPLANTATION Procedure Type within Indication, by Year 2006 J Heart Lung Transplant 2006;25:880-892 ISHLT

16. ADULT LUNG TRANSPLANTATION: Indications for Single Lung Transplants (Transplants: January 1995 - June 2005) ISHLT 2006 *Other includes: Sarcoidosis: 2.1% Bronchiectasis: 0.4% Congenital Heart Disease: 0.2% LAM: 0.8% OB (non-ReTx): 0.7% Miscellaneous:4.8% J Heart Lung Transplant 2006;25:880-892

17. ADULT LUNG TRANSPLANTATION: Indications for Bilateral/Double Lung Transplants (Transplants: January 1995 - June 2005) ISHLT 2006 *Other includes: Sarcoidosis: 2.9% Bronchiectasis: 4.8% Congenital Heart Disease: 1.7% LAM: 1.3% OB (non-ReTx): 1.1% Miscellaneous:0.9% J Heart Lung Transplant 2006;25:880-892

18. ADULT LUNG TRANSPLANTATION Indications By Year (%) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

19. ADULT LUNG TRANSPLANTATION Indications By Year (Number) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

20. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Era (Transplants: January 1988 – June 2004) Survival comparisons by era 1988-94 vs. 1995-99: p = 0.0294 1988-94: vs. 2000-6/03: p <0.0001 1995-99 vs. 2000-6/03: p <0.0001 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

21. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Age Group (Transplants: January 1990 – June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

22. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Gender (Transplants: January 1994 – June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

23. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis (Transplants: January 1994 – June 2004) Year ALPHA-1 (N=1,074) CF (N=1,970) COPD (N=4,989) IPF (N=2,318) PPH (N=557) SARCOIDOSIS (N=312) 176.780.481.871.265.867.8 361.365.564.055.056.654.9 551.254.148.743.146.749.5 741.144.935.733.038.544.5 1031.533.918.818.726.937.1 Survival comparisons Alpha-1 vs. CF: p = 0.0327 CF vs. IPF: p < 0.0001 Alpha-1 vs. IPF: p <0.0001CF vs. Sarcoidosis: p = 0.0041 Alpha-1 vs. PPH: p = 0.0032PPH vs. COPD: p = 0.0162 CF vs. COPD: p < 0.0001COPD vs. IPF: p <0.0001 Note: Other comparisons are not statistically different. ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

24. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 3 Months (Transplants: January 1994 – June 2004) Year ALPHA-1 (N=905) CF (N= 1,668) COPD (N= 4,402) IPF (N= 1,848) PPH (N= 393) SARCOIDOSIS (N=243) 188.490.990.286.190.084.2 370.774.070.666.577.368.2 559.161.253.752.163.861.5 747.450.739.439.952.655.3 1036.338.320.722.636.846.1 Survival comparisons Alpha-1 vs. IPF: p = 0.0004Alpha-1 vs. COPD: p = 0.0021 CF vs. COPD: p < 0.0001CF vs. IPF: p < 0.0001 PPH vs. COPD: p < 0.0001PPH vs. IPF: p < 0.0001 IPF vs. Sarcoidosis: p = 0.0222 Note: Other comparisons are not statistically different. ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

25. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 1 Year (Transplants: January 1994 – June 2004) Year ALPHA-1 (N=772) CF (N=1,438) COPD (N= 3,820) IPF (N=1,510) PPH (N= 341) SARCOIDOSIS (N=196) 1100.0 380.081.278.377.285.981.0 566.867.159.660.570.973.1 753.655.743.646.358.565.7 1041.042.023.026.240.954.8 Survival comparisons Alpha-1 vs. IPF: p = 0.0019Alpha-1 vs. COPD: p < 0.0001 CF vs. COPD: p < 0.0001CF vs. IPF: p < 0.0001 PPH vs. COPD: p < 0.0001PPH vs. IPF: p < 0.0001 COPD vs. Sarcoidosis: p = 0.0002IPF vs. Sarcoidosis: p = 0.0012 Note: Other comparisons are not statistically different. ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

26. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis (Transplants: January 1994 – June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

27. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 3 Months (Transplants: January 1994 – June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

28. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Diagnosis Conditional on Survival to 1 Year (Transplants: January 1994 – June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

29. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival for Eisenmengers Syndrome (Transplants: January 1990 – June 2004) ISHLT 2006 N at risk at 5 years = 35 N at risk at 5 years = 15 P=0.2787 J Heart Lung Transplant 2006;25:880-892

30. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Procedure Type (Transplants: January 1990 – June 2004) Diagnosis: Alpha-1 Antitrypsin Deficiency P < 0.0001 ISHLT 2006 N at risk at 10 years is 46 for Single Lung and 33 for Double Lung. J Heart Lung Transplant 2006;25:880-892

31. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival By Procedure Type and Age (Transplants: January 1990 – June 2004) Diagnosis: Alpha-1 Antitrypsin Deficiency ISHLT 2006 N at risk at 5 years: Single Lung, <50 = 125; Double Lung, <50 = 134; Single Lung, 50+ = 89; Double Lung, 50+ = 48 p = 0.0055 J Heart Lung Transplant 2006;25:880-892

32. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2004) Diagnosis: Emphysema/COPD P < 0.0001 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

33. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Age (Transplants: January 1990 – June 2004) Diagnosis: Emphysema/COPD P < 0.0001 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

34. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2004) Diagnosis: Idiopathic Pulmonary Fibrosis P = 0.2038 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

35. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type (Transplants: January 1990 – June 2004) Diagnosis: Primary Pulmonary Hypertension P = 0.1801 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

36. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2004) Diagnosis: Emphysema/COPD, Single Lung ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

37. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2004) Diagnosis: Emphysema/COPD, Double Lung ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

38. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2004) Diagnosis: Idiopathic Pulmonary Fibrosis, Single Lung ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

39. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Procedure Type and Era (Transplants: January 1990 – June 2004) Diagnosis: Idiopathic Pulmonary Fibrosis, Double Lung ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

40. ADULT LUNG TRANSPLANTATION Kaplan-Meier Survival by Donor CMV status/Recipient CMV status (Transplants: October 1999 – June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

41. ADULT LUNG TRANSPLANTS (1995-6/2004) Risk Factors for 1 Year Mortality (N=13,168) ISHLT 2006 *Other = All diagnoses other than COPD, PPH, IPF, cystic fibrosis, pulmonary fibrosis, bronchiectasis, alpha-1 antitrypsin deficiency, and LAM. J Heart Lung Transplant 2006;25:880-892

42. ADULT LUNG TRANSPLANTS (1995-6/2004) Risk Factors for 1 Year Mortality (N=13,168) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

43. ADULT LUNG TRANSPLANTS (1995-6/2004) Risk Factors for 1 Year Mortality (N=13,168) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

44. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

45. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Recipient Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

46. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Donor Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

47. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Donor Weight ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

48. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Pre-Transplant Recipient BMI ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

49. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Center volume ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

50. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Recipient FEV1 (% predicted) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

51. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Recipient Pre-Transplant Bilirubin ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

52. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Recipient Oxygen Required at Rest ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

53. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Risk Factors for 1 Year Mortality Recipient PVR ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

54. ADULT LUNG TRANSPLANTS (1995-6/2003) Factors Not Significant for 1 Year Mortality Recipient factors: pCO 2, transfusions, recent infection requiring IV drug therapy, diabetes, sternotomy, dialysis, FVC, creatinine, PRA, chronic steroid use Donor factors: History of hypertension, history of cancer, cause of death, height Transplant factors: Height ratio, BMI ratio, ischemia time ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

55. ADULT LUNG TRANSPLANTS (1995-6/2004) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality (N=4,581) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

56. ADULT LUNG TRANSPLANTS (1995-6/2004) Diagnosis = COPD/Emphysema Borderline Significant Risk Factors for 1 Year Mortality (N=4,581) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

57. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

58. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Recipient Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

59. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Center volume ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

60. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Donor Weight ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

61. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = COPD/Emphysema Risk Factors for 1 Year Mortality Recipient FEV1 (% predicted) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

62. ADULT LUNG TRANSPLANTS (1995-6/2004) Diagnosis = Cystic Fibrosis Risk Factors for 1 Year Mortality (N=1,806) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

63. ADULT LUNG TRANSPLANTS (1995-6/2004) Diagnosis = Cystic Fibrosis Borderline Significant Risk Factors for 1 Year Mortality (N=1,806) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

64. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = Cystic Fibrosis Risk Factors for 1 Year Mortality ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

65. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = Cystic Fibrosis Risk Factors for 1 Year Mortality Center volume ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

66. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = Cystic Fibrosis Risk Factors for 1 Year Mortality Donor BMI ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

67. ADULT LUNG TRANSPLANTS (1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality (N=2,151) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

68. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

69. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

70. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Donor Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

71. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient PA Diastolic Pressure ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

72. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Donor Weight ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

73. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient O 2 Required at Rest ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

74. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Center volume ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

75. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Recipient BMI ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

76. ADULT LUNG TRANSPLANTS (1/1995-6/2004) Diagnosis = IPF Risk Factors for 1 Year Mortality Ischemia Time ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

77. ADULT LUNG TRANSPLANTS (1995-6/2000) Risk Factors for 5 Year Mortality (N=7,072) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

78. ADULT LUNG TRANSPLANTS (1995-6/2000) Risk Factors for 5 Year Mortality (N=7,072) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

79. ADULT LUNG TRANSPLANTS (1995-6/2000) Borderline Significant Risk Factors for 5 Year Mortality (N=7,072) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

80. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

81. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Recipient Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

82. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Donor Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

83. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Pre-Transplant Recipient BMI ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

84. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Donor Height ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

85. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Center Volume ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

86. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Recipient PA Systolic Pressure ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

87. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Oxygen Required at Rest ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

88. ADULT LUNG TRANSPLANTS (1995-6/2000) Factors Not Significant for 5 Year Mortality Recipient factors: Chronic steroid use, transfusions, history of malignancy, cardiac output, PRA, FVC, FEV1, PCO 2, pulmonary vascular resistance, dialysis, recent infection requiring IV drug therapy Donor factors: Clinical infection, history of hypertension, history of cancer, history of diabetes, height Transplant factors: Ischemia time ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

89. ADULT LUNG TRANSPLANTS (1995-6/2000) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,111) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

90. ADULT LUNG TRANSPLANTS (1995-6/2000) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,111) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

91. ADULT LUNG TRANSPLANTS (1995-6/2000) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,111) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

92. ADULT LUNG TRANSPLANTS (1995-6/2000) Borderline Significant Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year (N=5,111) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

93. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Conditional on Survival to 1 Year ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

94. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

95. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Donor Age ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

96. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Recipient BMI ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

97. ADULT LUNG TRANSPLANTS (1/1995-6/2000) Risk Factors for 5 Year Mortality Conditional on 1 Year Survival Donor Height ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

98. ADULT LUNG TRANSPLANTS (1995-6/2000) Factors Not Significant for Conditional 5 Year Mortality Recipient factors: Ventilator, inotropes, hospitalized at transplant, pCO 2, gender, chronic steroid use, transfusions, history of malignancy, PRA, repeat transplant, FEV1, FVC, PA pressures, O 2 required, bilirubin, creatinine, recent infection requiring use of IV drug therapy, thoracotomy, cardiac output Donor factors: Gender, clinical infection, history of hypertension, history of cancer, history of diabetes, height, weight ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

99. ADULT LUNG TRANSPLANTS (1995-6/2000) Factors Not Significant for Conditional 5 Year Mortality Transplant factors: ABO compatibility, CMV mismatch, transplant center volume Post-transplant factors: Stroke prior to discharge, prolonged graft dysfunction prior to discharge, treated for rejection prior to discharge ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

100. ADULT LUNG RECIPIENTS Functional Status of Surviving Recipients (Follow-ups: April 1994 – June 2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

101. ADULT LUNG RECIPIENTS Employment Status of Surviving Recipients (Follow-ups: April 1994 – June 2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

102. ADULT LUNG RECIPIENTS: Rehospitalization Post-transplant of Surviving Recipients (Follow-ups: April 1994 - June 2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

103. ADULT LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2002 - June 2005) Analysis limited to patients receiving prednisone ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

104. ADULT LUNG RECIPIENTS Induction Immunosuppression (Transplants: January 2000 - December 2004) Analysis limited to patients receiving prednisone ISHLT 2006 Any Induction Polyclonal ALG/ATG OKT3 IL2R-antagonist J Heart Lung Transplant 2006;25:880-892

105. SURVIVAL BY INDUCTION USAGE For Adult Lung Recipients (Transplants: April 1994-June 2004) Conditional on survival to 14 days ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

106. SURVIVAL BY INDUCTION USAGE For Adult Lung Recipients (Transplants: January 2000-June 2004) Conditional on survival to 14 days ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

107. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2002 through June 2005 Analysis limited to patients receiving prednisone NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

108. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2002 through June 2005 Analysis limited to patients receiving prednisone NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

109. ADULT LUNG RECIPIENTS Maintenance Immunosuppression at Time of Follow-up For follow-ups between January 2002 through June 2005 Analysis limited to patients receiving prednisone 1 Year Follow-up (N = 3,482)5 Year Follow-up (N = 1,569) NOTE: Different patients are analyzed in Year 1 and Year 5 ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

110. ADULT LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2002 through June 2005 Conventional Combinations Analysis limited to patients receiving prednisone ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

111. ADULT LUNG RECIPIENTS Maintenance Immunosuppression Drug Combinations at Time of Follow-up For follow-ups between January 2002 through June 2005 Other Combinations Analysis limited to patients receiving prednisone ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

112. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Type of Induction (Transplants: January 1, 2000 - June 30, 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

113. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Type of Induction (Transplants: January 1, 2000 - June 30, 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

114. NUMBER OF REJECTION EPISODES FOR ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Type of Induction (Transplants: January 1, 2000 - June 30, 2004) No induction vs. polyclonal (p < 0.0001); no induction vs. IL2R (p = 0.009); polyclonal vs. IL2R (p = 0.032). ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

115. NUMBER OF REJECTION EPISODES FOR ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Type of Induction (Transplants: January 1, 2000 - June 30, 2004) 18-34: no induction vs. polyclonal (p = 0.002); no induction vs. IL2R (p = 0.022); 50-59: no induction vs. polyclonal (p = 0.0007); polyclonal vs. IL2R (p = 0.031); Females: no induction vs. polyclonal (p = 0.03); no induction vs. IL2R (p = 0.025); Males: no induction vs. polyclonal (p = 0.0003); polyclonal vs. IL2R (p = 0.0087) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

116. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Maintenance Immunosuppression (Transplants: January 1, 2000 - June 30, 2004) CyA + MMF vs. TAC + MMF (p = 0.004); CyA + AZA vs. TAC + MMF (p < 0.0001); CyA + AZA vs. TAC + AZA (p < 0.0001) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

117. PERCENTAGE OF ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Maintenance Immunosuppression (Transplants: January 1, 2000 - June 30, 2004) 18-49: CyA + AZA vs. TAC + MMF (p = 0.0138) 50-59: CyA + MMF vs. TAC + MMF (p = 0.0062); CyA + MMF vs. TAC + AZA (p = 0.0035); CyA + AZA vs. TAC + MMF (p = 0.0015); CyA + AZA vs. TAC + AZA (p = 0.0015) 60+: CyA + AZA vs. TAC + MMF (p = 0.0011); CyA + MMF vs. CyA + AZA (p = 0.0054) Females: CyA + AZA vs. TAC + MMF (p = 0.006); CyA + AZA vs. TAC + AZA (p = 0.0097) Males: CyA + MMF vs. TAC + MMF (p = 0.0078); CyA + AZA vs. TAC + MMF (p < 0.0001); CyA + AZA vs. TAC + AZA (p = 0.0031) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

118. NUMBER OF REJECTION EPISODES FOR ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Maintenance Immunosuppression (Transplants: January 1, 2000 - June 30, 2004) CyA + MMF vs. CyA + AZA (p = 0.002); CyA + AZA vs. TAC + MMF (p < 0.0001); TAC + MMF vs. TAC + AZA (p = 0.029) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

119. NUMBER OF REJECTION EPISODES FOR ADULT LUNG TRANSPLANT RECIPIENTS TREATED FOR REJECTION IN 1ST YEAR Stratified by Maintenance Immunosuppression (Transplants: January 1, 2000 - June 30, 2004) 18-49: CyA + MMF vs. TAC + MMF (p = 0.023); 60+: CyA + MMF vs. CyA + AZA (p = 0.009); CyA +AZA vs. TAC + MMF (p = 0.0038); Female: CyA + AZA vs. TAC + MMF (p = 0.0003); Male: CyA + AZA vs. TAC + MMF (p = 0.047); CyA + MMF vs. CyA + AZA (p = 0.006) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

120. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 Year Post-Transplant (Follow-ups: April 1994 - June 2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

121. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 1 and 5 Years Post-Transplant (Follow-ups: April 1994 - June 2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

122. POST-LUNG TRANSPLANT MORBIDITY FOR ADULTS Cumulative Prevalence in Survivors within 10 Years Post-Transplant (Follow-ups: April 1994 - June 2004) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

123. FREEDOM FROM BRONCHIOLITIS OBLITERANS For Adult Lung Recipients (Follow-ups: April 1994-June 2005) Conditional on Survival to 14 days ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

124. FREEDOM FROM BRONCHIOLITIS OBLITERANS STRATIFIED BY INDUCTION USE For Adult Lung Recipients (Follow-ups: April 1994-June 2004) Conditional on Survival to 14 days ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

125. FREEDOM FROM SEVERE RENAL DYSFUNCTION * For Adult Lung Recipients (Follow-ups: April 1994-June 2005) * Severe renal dysfunction = Creatinine > 2.5 mg/dl, dialysis or renal transplant ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

126. MALIGNANCY POST-LUNG TRANSPLANTATION FOR ADULTS Cumulative Prevalence in Survivors (Follow-ups: April 1994 - June 2005) Malignancy/Type1-Year Survivors5-Year Survivors7-Year Survivors No Malignancy 7968 (96.2%)1756 (87.5%)723 (81.3%) Malignancy (all types combined) 316 (3.8%)252 (12.5%)166 (18.7%) Malignancy Type* Skin 70132101 Lymph 1525431 Other 737151 Type Not Reported 21102 * Recipients may have experienced more than one type of malignancy so sum of individual malignancy types may be greater than total number with malignancy. Other malignancies reported include: adenocarcinoma (2; 2; 2), bladder (2; 1; 0), lung (2; 4; 2), breast (1; 5; 4); prostate (0; 5; 3), cervical (1; 1; 1); liver (1; 1; 1). Numbers in parentheses represent the number of reported cases within each time period. ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

127. FREEDOM FROM MALIGNANCY For Adult Lung Recipients (Follow-ups: April 1994-June 2005) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892

128. ADULT LUNG TRANSPLANT RECIPIENTS: Cause Of Death (Deaths: January 1992- June 2005) CAUSE OF DEATH 0-30 Days (N = 1,273) 31 Days - 1 Year (N = 1,886) >1 Year - 3 Years (N = 1,581) >3 Years - 5 Years (N = 910) >5 Years (N = 1,001) BRONCHIOLITIS 5 (0.4%)87 (4.6%)414 (26.2%)263 (28.9%)265 (26.5%) ACUTE REJECTION 65 (5.1%)37 (2.0%)26 (1.6%)5 (0.5%)7 (0.7%) LYMPHOMA 1 (0.1%)51 (2.7%)35 (2.2%)14 (1.5%)31 (3.1%) MALIGNANCY, OTHER 1 (0.1%)50 (2.7%)94 (5.9%)73 (8.0%)89 (8.9%) CMV 069 (3.7%)21 (1.3%)4 (0.4%)3 (0.3%) INFECTION, NON-CMV 270 (21.2%)685 (36.3%)395 (25.0%)172 (18.9%)180 (18.0%) GRAFT FAILURE 361 (28.4%)359 (19.0%)278 (17.6%)169 (18.6%)170 (17.0%) CARDIOVASCULAR 131 (10.3%)82 (4.3%)53 (3.4%)43 (4.7%)52 (5.2%) TECHNICAL 107 (8.4%)50 (2.7%)11 (0.7%)2 (0.2%)3 (0.3%) OTHER 332 (26.1%)416 (22.1%)254 (16.1%)165 (18.1%)201 (20.1%) ISHLT 2006 J Heart Lung Transplant 2006;25:880-892